Key points in hepatitis C guidance 2023 update： American Association for the Study of Liver Diseases-Infectious Diseases Society of America recommendations for testing， managing， and treating hepatitis C virus infection
10.3969/j.issn.1001-5256.2023.12.008
- VernacularTitle:《美国肝病学会/美国感染病学会丙型肝炎指导意见：HCV感染的检测、管理和治疗（2023年更新）》意见要点
- Author:
Huiying RAO
1
Author Information
1. Peking University People’s Hospital， Peking University Hepatology Institute， Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases， Beijing 100044， China
- Publication Type:Journal Article
- Keywords:
Hepatitis C;
Direct-Acting Antivirals;
Therapeutics;
Practice Guideline
- From:
Journal of Clinical Hepatology
2023;39(12):2798-2803
- CountryChina
- Language:Chinese
-
Abstract:
The Infectious Diseases Society of America and the American Association for the Study of Liver Diseases have collaboratively developed evidence-based guidance regarding the diagnosis， management， and treatment of hepatitis C virus （HCV） infection since 2013. A panel of clinicians and investigators with extensive expertise in infectious diseases or hepatology specific to HCV infection periodically reviews related evidence and update existing recommendations or introduce new recommendations based on such evidence. This update focuses on the changes to the guidance since the update in 2020， including recommendations for extensive universal screening， simplified treatment and testing regimens， treatment of poor compliance， and management of unique and key populations such as children aged <3 years and patients undergoing transplantation.
